Introduction
AML is the most common acute leukemia in adults. Its annual incidence in ailand is 1.4 per 100,000 population, with 5-year disease-free survival and overall-survival rates of 41.0% and 22.2%, respectively [1] . e most e cient chemotherapeutic agents are anthracyclin and Ara-C. Ara-C is administered as a standard dose during induction and a high dose during consolidation. Besides bone marrow suppression, nausea, vomiting, fatigue, and mouth sores, the side e ects of high-dose Ara-C (HIDAC) include conjunctivitis and cerebellar toxicity. PC/PEEF, a rare but often lethal complication of standard and high-dose Ara-C, was rst reported in 1984 [2] . No management guidelines exist for PC/PEEF. Based on a literature review and our experience with an AML patient with this rare complication after Ara-C treatment, we propose a strategy to manage it and rechallenge with Ara-C without the complication.
Case Report
A 38-year-old female presented with fatigue for 2 months. On examination, pale skin and petechiae along both legs were observed; others were unremarkable. e initial blood count showed a hemoglobin of 7.8 g/dL, WBC of 242.7 × 10 9 /L (myeloblasts and monoblasts constituted over 90%), and platelet count of 21 ×10 9 /L. By ow cytometry, the malignant cells (86%) were positive for CD13, CD33, CD11b, CD11c, CD14, CD64, CD117, and MPO which were compatible with AML-M4 according to FAB classi cation. By G-banding karyotyping, no abnormalities were observed. After establishing the diagnosis of AML, the patient received standard remission induction therapy with Ara-C (100 mg/M 2 /day; 12-hour continuous infusion once daily for 7 consecutive days) and idarubicin (12 mg/M 2 /day; intravenous infusion for 3 consecutive days). She regenerated at day 24 and entered complete remission without grade 4 complications except cytopenia. It was planned that she would receive allogeneic stem cell transplantation. While awaiting approval of this treatment from her covered medical expenses, we decided to control her disease with consolidation therapy, HIDAC regimen for 3 cycles.
A week after complete remission, Ara-C (1,000 mg/M 2 /day; 2-hour continuous infusion every 12 hours for 6 doses) commenced. On day 3 of this regimen, during administration of the fourth Ara-C dose, she complained of a sudden onset of dyspnea and sharp, persistent pain in the substernal and epigastric areas. She had no fever, sweating, cough, or palpitation. Her temperature was 36.8°C and pulse rate was 80/min and regular, but her blood pressure, measured repeatedly at all extremities, was 80/40 mmHg. A chest X-ray revealed massive cardiomegaly (Figure 1(b) ) relative to the baseline cardiac size on the admission day (Figure 1(a) ). Electrocardiography showed normal sinus rhythm and no low voltage, electrical alternans, or ST-T abnormality.
An echocardiography disclosed massive PEEF without cardiac tamponade. e left ventricular ejection fraction was 71% without either an abnormal wall motion or signi cant valve dysfunction. Computed tomography of the chest and abdomen was unremarkable except revealing massive PEEF. Troponin-T was under 0.003 ng/mL (<0.01 ng/mL), and CK-MB was 0.67 IU/L (5-25 IU/L). Viral serologic studies (herpes simplex virus, cytomegalovirus, Epstein-Barr virus, and hepatitis B virus) detected by IgM and IgG were all negative. Antinuclear antibody was also negative.
Given no other apparent causes of PC/PEEF, Ara-Cinduced PC/PEEF was highly suspected. After 2,000 mL of normal saline infusion within 15 minutes, hypotension was unimproved.
e initial central venous pressure revealed 24 cm H 2 O. Dopamine (10 µg/kg/minute) was started. Besides ceasing Ara-C, 10 mg/day of intravenous dexamethasone was initiated.
e substernal and epigastric pain subsequently disappeared within six hours, with BP stabilized at 110/80 mmHg. e inotropic drug was discontinued within 26 hours. e cardiac shadow was markedly decreased three days after commencement of the dexamethasone treatment. At day 7, an echocardiography revealed only small pericardial e usion, so a planned pericardiocentesis was canceled. e dexamethasone was tapered and stopped by day 11. She was discharged on day 23, still without evidence of e usion.
As Ara-C was deemed essential for the AML treatment, it was decided to repeat the HIDAC consolidation therapy but with preemptive, high-dose dexamethasone. Ten mg/day intravenous dexamethasone was therefore initiated the day before cytoreduction and continued for 6 days of each cycle.
e HIDAC regimen administration went without complications. e patient successfully underwent a matched-sibling stem cell transplantation in July 2012. As of January 2017, she remains in remission.
Discussion
PC/PEEF is an uncommon, but potentially fatal, AML complication. Its pathogenesis is multifactorial, possibly resulting from the underlying disease, the concomitant infection, accompanying bleeding complications arising from thrombocytopenia or DIC, the chemotherapy, or radiation. us, Ara-C-induced PC/PEEF should always be an exclusion diagnosis. In our case, we excluded both virological and autoimmune pathogenesis. Despite the lack of cytology of the pericardial e usion, we deemed that leukemic involvement and hemorrhagic complications in this patient, who was in remission and without any complaints, could be ruled out.
us, this severe episode should be described to the cytoreductive regimen. Chemotherapeutic agents which have been reported to induce PC/PEEF include daunorubicin, doxorubicin, cyclophosphamide, bleomycin, and actinomycin D. Our patient received anthracycline six weeks before the development of PC/PEEF; the longest duration of anthracycline-induced PC/PEEF onset ever reported was 29 days. erefore, Ara-C is the most likely cause of PC/PEEF in our patient, rather than doxorubicin.
Ara-C-induced PC/PEEF was rst described by Vaickus in 1984 [2] ; a literature review revealed that only 10 patients (including our patient) have been reported. Interestingly, two patients developed two episodes of this complication [3, 4] . e pathogenesis of these severe complications is unclear, but type IV delayed hypersensitivity [4] [5] [6] [7] [8] [9] , anaphylaxis [10] , and direct toxicity to the endothelium [11] have been suggested. Table 1 tabulates previously published series of PC/PEEF. e onset of PC/PEEF varied between 2 and 29 days (median: 3 days) after receiving repeated doses of Ara-C. Most patients received the HIDAC regimen. Our patient developed PC/PEEF three days after HIDAC; we hypothesize that there was a type IV delayed hypersensitivity, compatible with such reactions developing within 10 days of the last exposure. To prove this, a cardiac muscle biopsy showing in ltration of T-lymphocytes would be required. Case Reports in Hematology [2] with the hypothesis of a delayed hypersensitivity or anaphylaxis, but the response was undesirable. is could be due to an insu cient amount of steroid being used (prednisolone 20 mg/day). Subsequently, Gillis introduced higher dose of steroid (hydrocortisone 200 mg/day), and the results were promising [5] , similar to our patient. Successful results with various types and dosage of corticosteroids, such as intravenous hydrocortisone (200 mg/day) and oral methylprednisolone (0.5 mg/kg/day), have been reported [6] [7] [8] . Furthermore, we insisted on using the HIDAC regimen for the second course of consolidation chemotherapy with prophylactic dexamethasone. As PC/PEEF did not reappear, we suggest that patients with Ara-C-induced PC/PEEF may be treated with the same regimen combined with a systemic high-dose corticosteroid. From our experience, the optimal dexamethasone dosage to prevent this complication is at least 8-10 mg/day, which is equivalent to hydrocortisone dose of 200-250 mg/day or prednisolone dose of 40-50 mg/day.
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